ŌURA Files Registration Statement for Proposed Initial Public Offering
ŌURA Files Registration Statement for Proposed Initial Public Offering
ŌURA, a leading health intelligence platform and maker of the world’s smallest smart ring, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.
Oura has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol “OURA.”
Goldman Sachs & Co. LLC, Morgan Stanley, J.P. Morgan, Allen & Company LLC, and Jefferies will act as joint lead book-running managers for the proposed offering. BofA Securities, Barclays, and Wells Fargo Securities will act as joint book-running managers. Citizens Capital Markets, KeyBanc Capital Markets, and Guggenheim Securities will act as book-running managers. Canaccord Genuity, Needham & Company, Raymond James, Rothschild & Co, Truist Securities, and William Blair will act as additional book-running managers. Robinhood Securities will act as a co-manager for the proposed offering.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from:
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com;
- Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014, or by email at prospectus@morganstanley.com;
- J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com;
- Allen & Company LLC, Attention: Prospectus Department, 711 Fifth Avenue, 9th floor, New York, NY 10022, by telephone at (212) 339-2220, or by email at allenprospectus@allenco.com; or
- Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ŌURA
ŌURA is a health intelligence platform designed to transform how people understand and manage their health in everyday life. Oura’s platform is anchored by Oura Ring, the world’s leading smart ring that empowers you to live healthier, longer. Oura supports millions of members worldwide across sleep, activity, stress, readiness, women’s health, metabolic health, and heart health. Oura Ring is purpose-built to leverage the finger's unique physiological advantages for photoplethysmography (PPG) measurement, producing a stronger signal than wrist-based wearables. The core metrics of the lightweight Oura Ring are scientifically validated against gold standards and the ring tracks 50+ health metrics continuously, empowering both individuals and thousands of research teams, healthcare providers, sports teams, and organizations. Trusted by an ecosystem of more than 1,200 partners, Oura is advancing the future of preventative health with privacy and security at the forefront.
Founded in Finland in 2013, Oura is headquartered in San Francisco with E.U. headquarters in Oulu, Finland.
Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260903685494/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
3 Stocks to Sell and 3 Stocks to Buy for October